MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis
Disease Markers · 08.10.2022 · 2022 · 1-9
DOI: 10.1155/2022/8040419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 08.10.2022. Verfasst von Ali Seyed Salehi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Be…. Hauptthemen laut MEDLINE: Circulating MicroRNA, MicroRNAs, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shahid Beheshti University of Medical Sciences, Research Institute for Gastroenterology and Liver Diseases.
Abstract (Originalsprache)
MicroRNA (miRNA) expression dysregulations in pancreatic ductal adenocarcinoma (PDAC) have been studied widely for their diagnostic and prognostic utility. By the use of bioinformatics-based methods, in our previous study, we identified some potential miRNA panels for diagnosis of pancreatic cancer patients from noncancerous controls (the screening stage). In this report, we used 142 plasma samples from people with and without pancreatic cancer (PC) to conduct RT-qPCR differential expression analysis to assess the strength of the first previously proposed diagnostic panel (consisting of miR-125a-3p, miR-4530, and miR-92a-2-5p). As the result, we identified significant upregulation for all the three considered miRNAs in the serum of PC patients. After that, a three-miRNA panel in serum was developed. The area under the receiver operating characteristic curves (AUC) for the panel were 0.850, 0.910, and 0.86, respectively, indicating that it had a higher diagnostic value than individual miRNAs. Therefore, we detected a promising three-miRNA panel in the plasma for noninvasive PC diagnosis (miR-125a-3p, miR-4530, and miR-92a-2-5p).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Biology, Faculty of Biological Science, Islamic Azad University, North Tehran Branch, Tehran, Iran.
- Bone and Joint Reconstruction Research Center, Department of Orthopedics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Roshanak Shams, Ali Behmanesh
Förderung
- Shahid Beheshti University of Medical Sciences
- Research Institute for Gastroenterology and Liver Diseases
Zitieren
APA
Seyed Salehi, A., Parsa-Nikoo, N., Roshan-Farzad, F., Shams, R., Fathi, M., Asaszadeh Aghdaei, H., & Behmanesh, A. (2022). MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis. Disease Markers, 2022, 1-9. https://doi.org/10.1155/2022/8040419
Vancouver
Seyed Salehi A, Parsa-Nikoo N, Roshan-Farzad F, Shams R, Fathi M, Asaszadeh Aghdaei H, et al. MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis. Disease Markers. 2022;2022:1-9. doi:10.1155/2022/8040419
BibTeX
@article{SeyedSalehi2022,
author = {Seyed Salehi, Ali and Parsa-Nikoo, Negar and Roshan-Farzad, Farnaz and Shams, Roshanak and Fathi, Mohadeseh and Asaszadeh Aghdaei, Hamid and Behmanesh, Ali},
title = {MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis},
journal = {Disease Markers},
year = {2022},
volume = {2022},
pages = {1--9},
doi = {10.1155/2022/8040419}
}
EUVIMED